Myovant Sciences
majority of women treated with who used at were free at week | Myovant Sciences
Company
Deck Type
Sector
Industry
Deck date
August 2022
Slide
18 of 34
Similar slides by Myovant Sciences
See diffirences between slides (animation)
Results
August 2022
reduced the impact of pain on activities as shown by pain domain domain phi | Myovant Sciences
Results
August 2022
achieved sustained reductions in non menstrual pelvic pain scores scores | Myovant Sciences
Results
August 2022
achieved sustained reductions in dysmenorrhea scores scores | Myovant Sciences
Results
August 2022
achieved significant response rates for non menstrual pelvic pain in spirit and rates | Myovant Sciences
Related slides by other companies
NeuroSense Therapeutics
Investor Presentation
October 2024
paradigm phase trial design | NeuroSense Therapeutics
Aeglea BioTherapeutics
Investor Presentation
April 2023
peace phase trial mobility assessed by and | Aeglea BioTherapeutics
Ocuphire Pharma
Results
March 2022
characteristics study eye | Ocuphire Pharma
Aeglea BioTherapeutics
Investor Presentation
May 2023
peace phase trial mobility assessed by and | Aeglea BioTherapeutics
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights